Efficacy of oral cholecalciferol on rhododendrol‐induced vitiligo: A blinded randomized clinical trial. Issue 4 (5th February 2018)
- Record Type:
- Journal Article
- Title:
- Efficacy of oral cholecalciferol on rhododendrol‐induced vitiligo: A blinded randomized clinical trial. Issue 4 (5th February 2018)
- Main Title:
- Efficacy of oral cholecalciferol on rhododendrol‐induced vitiligo: A blinded randomized clinical trial
- Authors:
- Watabe, Akiko
Yamasaki, Kenshi
Asano, Masayuki
Kanbayashi, Yumi
Nasu‐Tamabuchi, Mei
Terui, Hitoshi
Furudate, Sadanori
Kakizaki, Aya
Tsuchiyama, Kenichiro
Kimura, Yutaka
Ito, Yumiko
Kikuchi, Katsuko
Aiba, Setsuya - Abstract:
- Abstract: Rhododendrol (RD), 4‐(4‐hydroxyphenyl)‐2‐butanol, inhibits melanin synthesis and has been used for skin‐whitening cosmetic products. RD has been very effective in lightening skin pigmentation, but some persons have developed so‐called RD vitiligo, in which vitiligo starts on the face, neck and hands where topical RD has been applied and even extended over skin areas where RD has not been applied. RD vitiligo lesions in some patients have lasted for years and have been resistant to conventional vitiligo treatments. We examined the effects of cholecalciferol on RD vitiligo in a blinded randomized clinical trial. Forty‐eight female RD vitiligo patients were recruited for the trial and were randomized into two groups: the vitamin D (VD)‐intervention group that received daily 5000 IU cholecalciferol for 5 months and the control group. Three blinded investigators scored vitiligo improvement by comparing photographic images of baseline and at 5‐month observation. Serum 25(OH)D3 of RD vitiligo patients was not significantly different from age‐matched healthy volunteers. Twenty‐two in the VD‐intervention group and 23 in the control group completed the 5‐month observation. Serum 25(OH)D3 levels were significantly increased after the 5‐month VD intervention, while the control group did not change. The improvement scores were significantly higher in the VD‐intervention group than the control group. The improvement scores were positively correlated with the serum 25(OH)D3Abstract: Rhododendrol (RD), 4‐(4‐hydroxyphenyl)‐2‐butanol, inhibits melanin synthesis and has been used for skin‐whitening cosmetic products. RD has been very effective in lightening skin pigmentation, but some persons have developed so‐called RD vitiligo, in which vitiligo starts on the face, neck and hands where topical RD has been applied and even extended over skin areas where RD has not been applied. RD vitiligo lesions in some patients have lasted for years and have been resistant to conventional vitiligo treatments. We examined the effects of cholecalciferol on RD vitiligo in a blinded randomized clinical trial. Forty‐eight female RD vitiligo patients were recruited for the trial and were randomized into two groups: the vitamin D (VD)‐intervention group that received daily 5000 IU cholecalciferol for 5 months and the control group. Three blinded investigators scored vitiligo improvement by comparing photographic images of baseline and at 5‐month observation. Serum 25(OH)D3 of RD vitiligo patients was not significantly different from age‐matched healthy volunteers. Twenty‐two in the VD‐intervention group and 23 in the control group completed the 5‐month observation. Serum 25(OH)D3 levels were significantly increased after the 5‐month VD intervention, while the control group did not change. The improvement scores were significantly higher in the VD‐intervention group than the control group. The improvement scores were positively correlated with the serum 25(OH)D3 levels after the 5‐month intervention period but not before the treatment. This blinded randomized clinical trial showed favor in administrating 5000 IU cholecalciferol daily to RD vitiligo patients. … (more)
- Is Part Of:
- Journal of dermatology. Volume 45:Issue 4(2018)
- Journal:
- Journal of dermatology
- Issue:
- Volume 45:Issue 4(2018)
- Issue Display:
- Volume 45, Issue 4 (2018)
- Year:
- 2018
- Volume:
- 45
- Issue:
- 4
- Issue Sort Value:
- 2018-0045-0004-0000
- Page Start:
- 456
- Page End:
- 462
- Publication Date:
- 2018-02-05
- Subjects:
- 25(OH)D3 -- cholecalciferol -- randomized clinical trial -- rhododendrol -- vitiligo
Dermatology -- Periodicals
Dermatology -- Japan -- Periodicals
Skin -- Diseases -- Periodicals
616.5005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1346-8138 ↗
http://www.blackwell-synergy.com/loi/jde ↗
http://www.dermatol.or.jp/Journal/JD/index-e.html ↗
http://www.dermatol.or.jp/Journal/JD/index.html ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1346-8138.14244 ↗
- Languages:
- English
- ISSNs:
- 0385-2407
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4968.770000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 6403.xml